Cytokinetics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CEORobert I. Blum
CEORobert I. Blum
Employees498
Employees498
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded1997
Founded1997
Employees498
Employees498
CYTK Key Statistics
Market cap8.07B
Market cap8.07B
Price-Earnings ratio-10.47
Price-Earnings ratio-10.47
Dividend yield—
Dividend yield—
Average volume1.72M
Average volume1.72M
High today$67.99
High today$67.99
Low today$65.92
Low today$65.92
Open price$67.89
Open price$67.89
Volume1.37M
Volume1.37M
52 Week high$69.33
52 Week high$69.33
52 Week low$29.31
52 Week low$29.31
Stock Snapshot
With a market cap of 8.07B, Cytokinetics(CYTK) trades at $66.05. The stock has a price-to-earnings ratio of -10.47.
On 2025-12-01, Cytokinetics(CYTK) stock moved within a range of $65.92 to $67.99. With shares now at $66.05, the stock is trading +0.2% above its intraday low and -2.9% below the session's peak.
Trading volume for Cytokinetics(CYTK) stock has reached 1.37M, versus its average volume of 1.72M.
The stock's 52-week range extends from a low of $29.31 to a high of $69.33.
The stock's 52-week range extends from a low of $29.31 to a high of $69.33.
CYTK News
Simply Wall St 3d
The Bull Case For Cytokinetics Could Change Following Legal Scrutiny Into FDA Filings for AficamtenEarlier this week, Grabar Law Office announced an investigation on behalf of Cytokinetics shareholders into whether company officers and directors breached thei...
Analyst ratings
81%
of 21 ratingsBuy
81%
Hold
19%
Sell
0%
People also own
Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.